Published briefing
Aug 24, 2026
Full research review · published Aug 24, 3:49 PM ET
This is the briefing exactly as published on Aug 24, 2026. It is never edited afterwards, so figures and views in it are as of that date and may since have changed. It is a record, not current advice.
What changed this run
No 8/10-or-better idea was killed or closed. Four new 1-year longs cleared the bar: RARE, MLYS, TLN and NXT. RARE opened at 8/10 after Q2 revenue of $214M, reaffirmed 2026 revenue guidance of $730M-$760M, a 2027 profitability path, GENGLYCOS accelerated approval, a UX111 PDUFA on September 19, 2026, and GTX-102 Phase 3 Aspire data expected in September or October. MLYS opened at 8/10 with lorundrostat under FDA review for a December 22, 2026 PDUFA, $661.4M cash/investments, and launch funding into 2028. TLN opened at 8/10 after raising 2026 adjusted free cash flow guidance to $1.2B-$1.35B and confirming the revised AWS PPA transition. NXT opened at 8/10 after record Q1 FY2027 revenue of $935M, adjusted EBITDA of $233M, backlog above $5.5B, $1.214B cash, and FY2027 adjusted EBITDA guidance raised to $870M-$930M.
What to watch next
September 2: AVGO fiscal Q3 AI revenue and backlog commentary. September 10/24: INSW dividend record/pay dates. September 19: RARE UX111 PDUFA. Late September: MU fiscal Q4 earnings and first fiscal-2027 memory-cycle framing. October 22: NXT Q2 FY2027 earnings. October 28: NOW and META Q3 earnings. October 29: MLYS ICER meeting on aldosterone synthase inhibitors. October 30/early November: CCJ Q3 update. November 18: TLN estimated Q3 update. November 27: BBIO BBP-418 PDUFA. December 22: MLYS lorundrostat PDUFA.